653O Pembrolizumab (pembro) vs placebo as adjuvant therapy for patients (pts) with renal cell carcinoma (RCC): Patient-reported outcomes (PRO) in KEYNOTE-564Toni K. Choueiri,Piotr Tomczak, S.H. Park,Balaji Venugopal,Stefan Symeonides,J. Hajek,Tom Ferguson,Y.-H. Chang, J.-L. Lee,Naomi B. Haas,P. Sawrycki,Naveed Sarwar,Marine Gross-Goupil,Antoine Thiery-Vuillemin, M. Mahave, T. Saretsky,P. Zhang,Jaqueline Willemann-Rogerio, David I. Quinn, T.B. PowlesANNALS OF ONCOLOGY（2021）引用 4|浏览10暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
